Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Offer Update

29 Jul 2005 18:04

Torex Retail PLC29 July 2005 Torex Retail plc29 July 2005 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN TOREX RETAIL PLC ___________________________________________________________________________ RECOMMENDED OFFER FOR XN CHECKOUT HOLDINGS PLC Offer Unconditional as to Acceptances As at 1.00 p.m. on 29 July 2005, valid acceptances had been received in respectof 24,777,251 XN Checkout Shares (representing approximately 89.19 per cent ofXN Checkout's issued share capital). Accordingly, the Board of Torex Retail plc("Torex Retail") announces that the offer (the "Offer") made by EvolutionSecurities Limited on behalf of Torex Retail for XN Checkout Holdings PLC ("XNCheckout") has been declared unconditional as to acceptances. The Offer remains conditional upon the admission to trading on AiM of the newTorex Shares issued as consideration under the Offer ("New Torex Shares")becoming effective. Application has therefore been made for the admission of 63,107,579 New TorexShares to trading on AiM and it is expected that these New Torex Shares will beadmitted to trading on AiM and that dealings in those shares will commence on 4August 2005, when it is also expected that the Offer will become whollyunconditional. Save for the holding of Christopher Moore (Chief Executive of Torex Retail andNon-Executive Chairman of XN Checkout) of 2,580,497 XN Checkout Shares, neitherTorex Retail nor any persons deemed to be acting in concert with it for thepurposes of the Offer owned any XN Checkout Shares (or rights over such shares)on 3 June 2005 (being the last dealing day prior to the commencement of theOffer period) nor has Torex Retail nor any person deemed to be acting in concertwith it for the purposes of the Offer acquired or agreed to acquire any XNCheckout Shares (or rights over such shares) during the Offer period other thanby way of acceptances of the Offer. On 10 June 2005, Torex Retail announced that irrevocable undertakings to acceptthe Offer had been received from XN Checkout Shareholders who, in aggregate,have an interest in 10,540,085 XN Checkout Shares. Valid acceptances have beenreceived in respect of 8,500,718 of these XN Checkout Shares (representingapproximately 30.60 per cent of XN Checkout's issued share capital) and theseare included in the total above. In respect of the balance of 2,039,367 XNCheckout Shares, the acceptance form has been received duly signed, but without,as yet, sufficient supporting documentation to treat it as a valid acceptanceand therefore has not been included in the total above. The Offer will remain open until further notice. At least 14 days' notice willbe given before the Offer is closed. Terms defined in the formal Offer document dated 8 July 2005 shall, unless thecontext requires otherwise, have the same meanings in this announcement. EnquiriesTorex Retail Telephone: 01993 230 030Richard Thompson / Nigel Horn Evolution Telephone: 0207 071 4300Tim Worlledge / Jeremy Ellis This announcement is issued by Evolution which is authorised and regulated inthe United Kingdom by the Financial Services Authority. Evolution is actingexclusively for Torex Retail and is acting for no one else in connection withthe Offer and will not be responsible to anyone other than Torex Retail forproviding the protections afforded to customers of Evolution nor for providingadvice in relation to the Offer. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Jul 20113:52 pmRNSIssue of Share Options
5th Jul 20111:30 pmRNSIssue of Equity
22nd Jun 20118:35 amRNSReceives EUR280,000 Grant Funding
13th Jun 20117:00 amRNSDirectorate Appointment
3rd Jun 201110:02 amRNSAGM Statement
11th May 20117:00 amRNSPositive Results in Clinical Evaluation of dCELL
4th May 20117:00 amRNSFinal Results
21st Apr 20117:00 amRNSTissue Regenix enters commercialisation agreement
29th Mar 20117:00 amRNSDirectorate Change
10th Mar 20117:00 amRNSNotice of allowance of patent received
4th Jan 201111:27 amRNSHolding(s) in Company
30th Dec 20109:05 amRNSHolding(s) in Company
23rd Dec 201012:44 pmRNSChange of Adviser
21st Dec 201010:12 amRNSAdviser - Change of Name
16th Dec 20107:00 amRNSResearch Update
10th Dec 20109:20 amRNSChange of Adviser
26th Nov 20103:12 pmRNSChange of Registered Office
23rd Nov 20105:18 pmRNSIssue of Equity
20th Oct 20107:00 amRNSHalf Yearly Report
18th Aug 20102:19 pmRNSHolding(s) in Company
10th Aug 20107:00 amRNSCE Mark Grant
5th Aug 20103:43 pmRNSPatents approved
1st Jul 201010:38 amRNSHolding(s) in Company
29th Jun 20104:37 pmRNSIssue of Equity
29th Jun 20108:06 amRNSFirst day dealings in Tissue Regenix
29th Jun 20107:00 amRNSFirst Day of Dealings
28th Jun 20102:20 pmRNSResult of General Meeting
10th Jun 20103:39 pmRNSSch 1 - Oxeco (to be renamed Tissue Regenix Group)
3rd Jun 20107:00 amRNSAcquisition
21st Apr 201011:20 amRNSResult of AGM
26th Mar 20107:00 amRNSFinal Results
11th Jan 20105:05 pmRNSHolding(s) in Company
23rd Dec 20091:49 pmRNSHolding(s) in Company
23rd Dec 200912:07 pmRNSHolding(s) in Company
22nd Dec 20094:33 pmRNSHolding(s) in Company
17th Dec 20093:50 pmRNSHolding(s) in Company
17th Dec 20092:47 pmRNSHolding(s) in Company
9th Dec 20099:28 amRNSInvesting Policy
23rd Oct 20097:00 amRNSInterim financial report
25th Aug 20092:30 pmRNSHolding(s) in Company
23rd Jul 20097:00 amRNSClosure of subsidiary business
2nd Jun 200912:00 pmRNSAppointment of Non-Executive Director
26th May 20093:00 pmRNSChange of Nominated Adviser Name
20th Apr 20097:00 amRNSFinal Results
24th Mar 200910:18 amRNSAppointment of Broker
18th Mar 200911:54 amRNSStrategic Review and Directorate Change
19th Nov 20087:00 amRNSDirectorate Change
16th Oct 20087:00 amRNSInterim Results
9th Jul 200812:39 pmRNSHolding(s) in Company
29th May 200812:10 pmRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.